Loading...
Loading IPO details...
RUBICON
LISTEDInvestors can bid for minimum 30 shares and in multiples. The table shows min-max investment by Retail and HNI.
| Application | Lots | Shares | Amount |
|---|---|---|---|
Retail(min) | 1 | 30 | ₹14,550 |
Retail(max) | 13 | 390 | ₹1.89L |
SHNI(min) | 14 | 420 | ₹2.04L |
SHNI(max) | 68 | 2,040 | ₹9.89L |
BHNI(min) | 69 | 2,070 | ₹10.04L |
Employee(min) | 1 | 30 | ₹12,450 |
Employee(max) | 34 | 1,020 | ₹5.00L |
Note: Lot size is 30 shares at ₹485/share (₹₹14,550/lot).Limits: Retail ₹0-₹2L, sHNI ₹2L-₹10L, bHNI >₹10L.
Rubicon Research Limited is an Indian pharmaceutical formulations company with a focus on regulated markets, especially the US. It has a portfolio of 72 active ANDA and NDA products approved by the US FDA and had 66 commercialized products generating USD 195 million revenue in FY24. The company is strongly driven by innovation and research & development, with a 75.89% CAGR revenue growth between FY23 and FY25.
Rubicon Research Limited is a high-growth pharmaceutical company with strong US market presence and robust fundamentals, but the IPO is priced at a premium valuation relative to peers. The grey market premium and positive demand suggest good listing gains potential. However, geographic concentration risk, regulatory uncertainties, and expensive valuation make it more suitable for investors aiming for short to medium-term listing gains rather than long-term value investing at this price.
Analyst Notes: Automated research generated via Perplexity AI